Home/Pipeline/Hepatic Denervation for Type 2 Diabetes

Hepatic Denervation for Type 2 Diabetes

Type 2 Diabetes

FeasibilityActive

Key Facts

Indication

Type 2 Diabetes

Phase

Feasibility

Status

Active

Company

Metavention

About Metavention

Metavention is a private, pre-revenue biotech company founded in 2010 and headquartered in Minneapolis, USA. It is advancing a catheter-based radiofrequency denervation platform targeting the sympathetic nervous system to treat hypertension and type 2 diabetes. The company is currently conducting multiple early-stage clinical studies (DeLIVER and MODUS) in the U.S., Australia, and New Zealand to evaluate the safety and performance of its iRF Denervation System for both renal and hepatic nerve ablation.

View full company profile

Therapeutic Areas

Cardiovascular Metabolic

Other Type 2 Diabetes Drugs

Drug	Company	Phase	Status
Diabetes Management Gel	Gelteq Limited	Formulation Development	Active
Tolimidone	Biodexa Pharmaceuticals	Phase 2	Acquired Asset
Generic Semaglutide Injection (Obeda)	Dr. Reddy's Laboratories	Approved	Launched in India
BioChaperone® Lispro	Adocia	Phase 3	Active
BioChaperone® Combo (Insulin Glargine / Lixisenatide)	Adocia	Phase 2	Active
Metformin API	USV Biologics Division	Commercial	Active
Empagliflozin	Azico Biophore	Commercial	Active
Sitagliptin Intermediate	AR Life Science	Commercial	Active
AJN003 (LuCI™)	AltrixBio	Pre-clinical	Advancing to Phase 1 (planned 2026)
Sitagliptin Phosphate Polymorph	Morepen Laboratories	Pre‑clinical	Active
MVD-1 (SANA)	Eolo Pharma	Discovery	Active
Type 2 Diabetes Management	iWel	Development	Active